ReMEDy2 Phase 2/3 AIS Clinical Developments: Progress continues with site activation activities accelerating. As part of this, DiaMedica has selected and prioritized fifteen research centers in the United States that are anticipated to be top enrollment centers. “Our clinical team is energized by the progress made over the past 90 days and is eager to activate and better support our high-volume centers,” stated Dr. Lorianne Masuoka, DiaMedica’s Chief Medical Officer. “We are also pleased to report that there have been no cases of hypotension in newly enrolled participants.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Therapeutics files to sell 4.72M shares of common stock for holders
- DiaMedica Therapeutics 10% holders buy $6M in common stock
- Biotech Alert: Searches spiking for these stocks today
- Diamedica Therapeutics Expands Trials to Address Preeclampsia
- DiaMedica to issue 4.72M shares at $2.50 per share in private placement
Questions or Comments about the article? Write to editor@tipranks.com